27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- HC Wainwright has assumed coverage on Scholar Rock Holding Corp (NASDAQ:SRRK) with a Buy rating and price target of $30.
- The analyst writes that with a positive readout from the Phase 2 TOPAZ study under their belt, Scholar Rock’s apitegromab (SRK-015) is shaping to be a transformative therapeutic for Type 2/3 Spinal Muscular Atrophy (SMA).
- HC Wainwright says that recent 24-Month TOPAZ extension data further convinces that apitegromab can solidify a place in the SMA market (2025 est. approval) by being a muscle-directed therapy that can complement current SMN therapies.
- Apitegromab showed a mean HFMSE change of +4.4 points, with 81% of patients achieving a ≥1 point increase and 56% achieving ≥3 points.
- Scholar Rock is currently enrolling patients for its pivotal Phase 3 SAPPHIRE study, which KOLs indicate may deliver equal, if not better results, as the design is influenced by TOPAZ.
- Price Action: SRRK shares are up 2.75% at $9.16 on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!